Skip to main content
SpringerLink
Log in

Comment on “Preclinical assessment of histone deacetylase inhibitor quisinostat as a therapeutic agent against esophageal squamous cell carcinoma”

  • Letters to the Editor
  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Abstract

Recently, we read a paper “Preclinical assessment of histone deacetylase inhibitor quisinostat as a therapeutic agent against esophageal squamous cell carcinoma” published in Investigational New Drugs. Quisinostat may be a promising drug candidate for the treatment of esophageal squamous cell carcinoma. However, some problems existing in the methods part of this paper are worthy of comment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Data availability

All data generated or analysed during this study are included in this published article.

References

  1. Zhong L, Zhou S, Tong RS, Shi JY, Bai L, Zhu YX, Duan XM, Liu WZ, Bao JK, Su LY, Peng Q (2019) Preclinical assessment of histone deacetylase inhibitor quisinostat as a therapeutic agent against esophageal squamous cell carcinoma[J]. Invest New Drugs 37(4):616–624

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Oncology, Affiliated Hospital of Guangdong Medical University, No. 27 South of Ren Min Road, Zhanjiang, 524200, Guangdong, China

    Jiong Lin

Authors
  1. Jiong Lin
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Study concept and design, data analysis, methodology, drafting manuscript, review and editing, supervision, J.L.

Corresponding author

Correspondence to Jiong Lin.

Ethics declarations

Ethics approval and consent to participate

This article does not contain any studies with human participants or animals performed by any of the authors. 

Consent for publication

Authors have approved the article to be published.

Research involving human participants and /or animals

None.

Informed consent

This article does not contain any studies with human participants or animals performed by any of the authors.

Conflict of interest

Author Jiong Lin declares that he has no conflict of interest. 

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lin, J. Comment on “Preclinical assessment of histone deacetylase inhibitor quisinostat as a therapeutic agent against esophageal squamous cell carcinoma”. Invest New Drugs 39, 1454–1455 (2021). https://doi.org/10.1007/s10637-021-01124-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10637-021-01124-3

Keywords

Search

Navigation